TVTX · Travere Therapeutics, Inc. · Stock research

Current Thesis

The July frame — approval binary spent, price sitting inside the target band, no sell-side headroom left — resolved on 2026-08-04. Q2 2026 revenue came in at $169.584M against a $159.589M consensus, adjusted EPS at $(0.10) against $(0.14), and the stock traded up more than 13% after hours. Six target raises followed inside four sessions: Citi to $85 and Evercore to $68 on 08-05, TD Cowen and Guggenheim to $75 on 08-05, Wedbush to $75 and Canaccord to $70 on 08-06, then Evercore again to $78 on 08-10. The 2026-08-14 close of $62.14 is 1.0% under the 52-week high of $62.76 and below every one of those marks. The leg an investor is buying is no longer a regulatory binary but a commercial ramp: FILSPARI US net product sales of $141.1M in Q2, +96% YoY, on 2,012 new patient start forms, across two indications of which FSGS has no approved competitor. What the next 30 days do not contain is anything that resolves it — three investor conferences and then a wait until the early-November print.

Bullish and bearish views on Travere Therapeutics, Inc.

The model's bull view on Travere Therapeutics, Inc. (TVTX), in brief: The ramp accelerated rather than plateaued. The bear view: Still GAAP loss-making, and the loss widened. Both cases follow in full.

Bull Case

• The ramp accelerated rather than plateaued. FILSPARI US net product sales $141.1M in Q2 2026, +96% YoY; first-half 2026 sales $246.2M, +93% YoY (2026-08-04 Q2 release). Total US net product sales of $161.4M compare with $94.8M in Q2 2025.
• Demand is measured in patients, not just dollars. 2,012 new patient start forms received in Q2 2026 — the disclosure that separates price/reimbursement effects from underlying prescriber adoption, and the number a Q3 print grades directly.
• Revenue beat the Street on the first full FSGS-contributing quarter. $169.584M reported vs $159.589M consensus; the FSGS indication received full FDA approval on 2026-04-14 as the first approved therapy for FSGS without nephrotic syndrome.
• The re-rating band moved up, not just the price. Post-print targets cluster at $70–$85 (Citi $85, Evercore $78 on 08-10, TD Cowen $75, Wedbush $75, Guggenheim $75, Canaccord $70) versus the $52–58 consensus range that bracketed spot through July.
• Balance sheet funds the launch. $489.2M cash and equivalents at 2026-06-30, following the 2026-05-11 close of $525M in 0.50% convertible senior notes due 2032 (≈$508.5M net proceeds) used to refinance the 2029 notes — the maturity wall moved out and the coupon dropped.
• Pipeline optionality was bought with cash, not equity. The civorebrutinib in-license from Everest Medicines closed in July 2026 with a $112.5M upfront payment. Chugai submitted a sparsentan NDA in Japan in June 2026, adding an ex-US royalty path.

Bear Case

• Still GAAP loss-making, and the loss widened. Q2 2026 net loss $34.8M ($0.37 per basic share) versus $12.8M ($0.14) in Q2 2025, on Q2 SG&A of $96.1M and R&D of $60.3M. The adjusted $(0.10) headline is $25.8M of add-backs away from the reported number.
• No company-set bar. The 2026-08-04 release disclosed no full-year 2026 revenue guidance. Street models carry the ramp with nothing from management anchoring them, which removes the guidance-raise mechanism that usually extends a launch re-rating between prints.
• The mark-up wave for this cycle has already been spent. Six raises landed between 08-05 and 08-10. There is no second sell-side revision cohort scheduled before Q3 results.
• IgAN — the larger revenue base — is contested. Novartis's Fabhalta and Vera Therapeutics' atacicept compete for the same nephrology prescriber. FSGS is the uncontested layer; headline FILSPARI totals blend the two, so a competitive share shift shows up late.
• Conversion overhang sits immediately overhead. The 2032 notes convert at approximately $64.90 per share, about 4.4% above the 2026-08-14 close of $62.14 — a reference the equity has to clear and hold before the converts stop acting as a supply-side ceiling.
• The bridge to the next pipeline datapoint is long. Pegtibatinase HARMONY Phase 3 topline is guided to 2H 2027. Nothing in the clinical portfolio prints inside 2026.

Setup & Price Structure

The narrative is accelerating, dated by the 2026-08-04 print, the 2026-08-05 gap higher, and the 08-05→08-10 target cluster into $70–$85. This is the third mark-up wave on the same story (April approval, mid-June, August print), which makes the label fragile rather than wrong: a Q3 print with start forms below the 2,012 booked in Q2, with no further target revisions, would put it in maturing.

Observables on crowding and positioning, stated without a verdict:

• The 2026-08-14 close of $62.14 is 1.0% below the 52-week high of $62.76; the three-month return is +45.9% and RSI(14) reads 64.5. Price is extended against its own base but not at a momentum extreme.
• Retail-facing coverage clustered tightly around the event ("TVTX Stock Rallies Over 13% After Hours", 2026-08-05) rather than spreading through the following week.
• The company issued $525M of converts on 2026-05-11 at a ~$64.90 conversion price, roughly 15% above where the stock traded through mid-July — issuance into strength, executed as a refinancing of the 2029 notes rather than as new equity.
• No earnings date falls inside the next 30 days. The catalyst gap runs from the September conference block to the early-November print.

The structure that matters: the 2026-08-05 gap is unfilled and the July range (07-07 close $57.85, 07-17 close $56.71) sits beneath it as the first shelf. A weekly close under that range is what would show the post-print re-rating round-tripping.

Catalyst Calendar (next 30 days)

• 2026-09-08 — Wells Fargo 21st Annual Healthcare Conference presentation. First management commentary since the Q2 call; watch for any framing of Q3 start-form trajectory.
• 2026-09-09 — Citi 2026 Biopharma Back to School Conference. Citi carries the high mark at $85 (2026-08-05); its own conference is where that model gets defended or softened.
• 2026-09-10, 9:10 a.m. ET — 2026 Cantor Global Healthcare Conference presentation.
• ~2026-11-03 (est.) — Q3 2026 results. Outside the 30-day window and the only event that grades the ramp; no company-confirmed date as of 2026-08-14.

What Would Change Our Mind

The structural break is the 2026-08-05 gap failing to hold. Price giving back the whole post-print move and closing back inside the July range would say the Q2 beat bought a re-rating the tape would not keep — concretely, a weekly close below $55, which sits under both the 07-07 close of $57.85 and the 07-17 close of $56.71.

On fundamentals, the number that would flip the read is the Q3 new patient start-form count. Q2 booked 2,012; a Q3 figure below that, with FILSPARI sequential growth decelerating, would mean the FSGS layer is a one-quarter step-up rather than a second growth curve — and would make the $70–$85 target band a set of stale marks.

The third condition is time. If the September 8–10 conference block passes with no incremental disclosure and price has not reclaimed the $62.76 high, the name becomes a two-month wait on a story where the sell-side revision cycle is already complete.

Correlation Notes

• LGND (Ligand Pharmaceuticals) holds a sparsentan royalty. Its royalty line is an independent, separately-audited read on FILSPARI units and moves on the same commercial datapoint.
• NVS (Novartis, Fabhalta) and VERA (atacicept) are the competitive reads on the IgAN base. Their nephrology disclosures matter more to the TVTX revenue mix than headline FILSPARI totals do.
• XBI / IBB — a company with a $34.8M GAAP quarterly loss and $489.2M of cash carries small/mid-cap biotech beta into rate moves and sector risk-appetite swings regardless of its own ramp.
• Chugai/Roche — the June 2026 Japanese NDA submission makes ex-US regulatory timing a partner-controlled variable rather than a Travere-controlled one.